FibroGen, Inc.
FGEN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.58 | -0.09 | -2.35 |
| FCF Yield | 59.14% | 0.35% | -2.29% | -0.84% |
| EV / EBITDA | -7.90 | -57.98 | -14.90 | -77.84 |
| Quality | ||||
| ROIC | -12.48% | -16.25% | -90.54% | -21.05% |
| Gross Margin | 93.69% | 90.80% | 83.23% | 88.57% |
| Cash Conversion Ratio | 0.14 | -1.67 | 0.59 | -1.69 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 368.70% | 108.83% | -261.87% | 78.79% |
| Safety | ||||
| Net Debt / EBITDA | -6.04 | -2.81 | -0.25 | 4.22 |
| Interest Coverage | -6.00 | -6.61 | -33.17 | -3.36 |
| Efficiency | ||||
| Inventory Turnover | 0.02 | 0.08 | -6.55 | 0.22 |
| Cash Conversion Cycle | -6,993.98 | -1,469.10 | -12.85 | 411.71 |